Linked Life Data

12201500

Source:http://linkedlifedata.com/resource/pubmed/id/12201500

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2002-8-30
pubmed:abstractText
Sixteen patients with stage IV melanoma, who were heavily pretreated, received 11 mg/m2/day of intravenous Irofulven for five consecutive days every 28 days. There were no objective tumor responses, although one patient exhibited stable disease after 4 cycles. The most common toxicities were grade 1/2 nausea, vomiting, fatigue, anemia, and thrombocytopenia. One patient required a dose reduction for an elevated creatinine while another patient required cessation of treatment because of acute ataxia that may have been related to Irofulven. Based upon these data, Irofulven does not demonstrate significant antitumor activity to warrant further investigation in advanced melanoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0167-6997
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
357-62
pubmed:dateRevised
2005-1-13
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma.
pubmed:affiliation
University of Colorado Cancer Center, Division of Medical Oncology, Anshutz Cancer Pavilion, Aurora 80010-0510, USA. aspierson@earthlink.com
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase II